Large arteries are comprised of vascular smooth muscle cells (SMCs) embedded within a complex, cell-derived extracellular matrix. Collagen and elastic fibers, the major constituents of the vascular matrix, are secreted and assembled by SMCs and confer tensile and elastic properties. In the medial layer of elastic arteries, elastin forms concentric fenestrated lamellar layers that intercalate with alternating rings of SMCs to form functional lamellar units. In the aorta, elastic fibers represent the largest component of the extracellular matrix, contributing up to 50% of aortic dry weight.

A series of elegant reports has demonstrated a critical role for elastin in the regulation of vascular morphogenesis in mice. Elastin (eln-null) mice die shortly after birth because of aortic obstruction by SMC proliferation. Heterozygous mice (eln +/−) are viable but produce ≈50% less elastin mRNA and protein; these animals are hypertensive, exhibit thinner elastic lamellae, more lamellar units, decreased aortic compliance, and mild cardiac hypertrophy compared with eln +/+ mice. Extensive experimental studies have revealed that elevated arterial pressure is an adaptation to maintain cardiac output and tissue perfusion in spite of vessel stiffness, whereas the increase in lamellar unit number is an adaptation to normalize wall stress.

In this issue of Circulation Research, Hirano et al report the phenotypic rescue of elastin-deficient mice by generation of a humanized elastin mouse. Using a bacterial artificial chromosome encoding the entire human elastin gene (hBAC), they engineered mice to express functional human elastin (ELN) under the control of its native promoter. Several transgenic founder lines demonstrated at least 1 functional ELN insert and were capable of producing human elastin mRNA. Spatial and temporal expression of the human ELN transgene was similar to endogenous mouse elastin. Moreover, the hBAC mRNA product was appropriately spliced, and the protein was correctly secreted, assembled, and incorporated into mouse elastic fibers.

At first glance, it may seem surprising that human elastin can substitute for mouse elastin, considering the differences in exon splicing and the lower than average amino acid conservation between species. In retrospect, however, Hirano et al might have expected the 2 proteins to be interchangeable, because it is primarily the structure of the elastin protein that is important for function. The alternating hydrophobic and crosslinking domains of elastin are conserved throughout vertebrate evolution, and it is this repetitive domain structure that promotes the self-assembly of elastin into fibrillar structures, provides elastomeric properties, and stabilizes elastin to withstand repeated cycles of extension and recoil.

Transgenic expression of human elastin prevented lethality in the eln-null mouse, although the rescued animals expressed only 30% of normal elastin levels. In accordance with the lower elastin content, these animals exhibited a more severe cardiovascular phenotype than eln +/+ mice, evidenced by stiffer vessels, higher blood pressure, and greater cardiac hypertrophy. Introduction of the hBAC into the eln +/+ mice increased elastin content by 40%, and this resulted in a decrease in lamellar unit number and arterial pressure to levels measured in eln +/+ mice, and partially restored vascular compliance. Taken together, these findings suggest a direct relationship between the amount of elastin produced (mouse and human combined) and the severity of the cardiovascular defect in mice. Thus, these mice might provide an elegant system for teasing apart the different thresholds for elastin expression which lead to specific abnormalities in elastic tissues. Indeed, these authors have also used this model to investigate elastin-dosing effects on lung development and susceptibility to smoke-induced emphysema.

In humans, ELN deficiency has been attributed to genetic diseases (reviewed by Milewicz et al14). However no relationship has been established between elastin protein levels and cardiovascular phenotype, although it likely exists based on the wide spectrum of cardiovascular disease severity in patients with elastin deficiencies. Some people hemizygous for ELN can survive into adulthood with little or no cardiovascular problems, whereas in others, the vascular system is severely compromised even before birth.15 There are clearly other factors, most likely a combination of genetic and environmental, that influence the severity of elastin-related arteriopathy in humans. Population-specific differences in exon splicing and elastin deposition have recently been identified,16 and 3 quantitative trait loci affecting elastin production have been mapped in rats.17 Future research in humans and rodents will focus on identifying these important modifier genes, because they will be crucial to implementing successful genetic therapies.

Although certain physiological parameters were improved in the hBAC-null animals, other key functions of elastin were not examined in the current study. Studies of eln +/+ mice have revealed that elastin is required to maintain SMC quiescence and circumferential orientation in vivo.1 These studies are consistent with in vitro findings that insoluble...
elastin maintains SMC quiescence, whereas incompletely assembled or degraded elastin peptides promote cell proliferation.\textsuperscript{18,19} Although other matrix molecules, such as type I collagen, have been implicated in maintaining SMC quiescence,\textsuperscript{20} the studies of elastin-deficient mice\textsuperscript{3,5,7} suggest that in the immediate perinatal phase of development, elastin is the dominant factor. However, the functional consequence of altered SMC orientation remains unclear, as do the mechanisms by which elastin is able to direct SMC orientation and inhibit proliferation. Preliminary studies by Karnik et al\textsuperscript{21} have begun to dissect these mechanisms, and it will be interesting to see how future studies define the processes involved.

Another benefit of the humanized mouse model is the potential to investigate aspects of \textit{ELN} function and pathology that are not evident in the \textit{eln} null or \textit{eln}\textsuperscript{+/−} mice. For example, supravalvular aortic stenosis (Online Mendelian Inheritance in Man no. 185500) is the most common cardiovascular manifestation of \textit{ELN} haploinsufficiency in humans and frequently requires surgical correction\textsuperscript{15}; however, the \textit{eln} \textit{+/−} mouse does not exhibit this phenotype. Hirano et al found that introduction of the hBAC to \textit{eln} \textit{+/−} mice leads to thickening of the ascending aorta, which may prove to be a better model to study SVAS. Moreover, using the humanized mouse, one can test the function of mutations in \textit{ELN} that produce less severe phenotypes than haploinsufficiency, for example, mutations that affect elastin durability or susceptibility to proteolytic degradation.

In the current study, Hirano et al report copy number–independent transgene expression coupled with very low expression levels, emphasizing the complexity of \textit{ELN} regulation and suggesting that the mouse milieu is inadequate to recapitulate normal human gene expression. Whether mouse tissues lack specific transcription factors required to drive \textit{ELN} expression or whether hBAC expression depends on distal regulatory sequences remains to be elucidated. However, as future studies define the missing regulatory elements, humanized mice expressing clusters of relevant genes, rather than individual genes, are likely to be developed. Establishment of normal \textit{ELN} expression levels in the mouse will provide the most valuable tool for studying \textit{ELN} and give the greatest opportunity for the development of strategies to treat diseases involving elastin deficiency.

**Sources of Funding**
Supported by the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Ontario (M.P.B.). M.P.B. is a Career Investigator of the Heart and Stroke Foundation of Ontario. P.J.A. holds a Canadian Graduate Scholarship Doctoral Research award from the Canadian Institutes of Health Research.

**Disclosures**
None.

**References**


Bouncing Back From Elastin Deficiency
Pamela J. Ahmad, Lucy R. Osborne and Michelle P. Bendeck

Circ Res. 2007;101:439-440
doi: 10.1161/CIRCRESAHA.107.160358
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/101/5/439

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/